Orforglipron 6mg Tablets | 100-Count | GLP-1 Receptor Agonist
🇺🇸 1-Region Domestic Shipping
QSC Orforglipron (Oral non-peptide GLP-1R agonist) — ≥99% HPLC purity, MS confirmed, Janoshik COA. Research use only.
* The information on this page is a summary and is not intended to cover all available information about this medication. It does not cover all possible uses, directions, precautions, drug interactions or adverse effects and is not a substitute for the expertise and judgement of your healthcare professional.
{“@context”: “https://schema.org”, “@type”: “FAQPage”, “mainEntity”: [{“@type”: “Question”, “name”: “How are QSC research tablets supplied?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “QSC research tablets are supplied as pre-dosed oral tablets at the stated concentration. No reconstitution is required. Each tablet is compressed at uniform dose for consistent dosing in research applications.”}}, {“@type”: “Question”, “name”: “How should research tablets be stored?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Store at room temperature (15–25°C) in a cool, dry place away from moisture, heat, and direct sunlight. Keep in the original container. Properly stored tablets remain stable for 2–3 years.”}}, {“@type”: “Question”, “name”: “What purity are QSC research tablets and how is it verified?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “QSC research tablets contain active ingredient at ≥99% HPLC purity before tableting, with MS-confirmed identity on every batch. COA is published on the product page and independently verifiable at verify.janoshik.com.”}}]}
What is Orforglipron?
Orforglipron (Oral non-peptide allosteric GLP-1R agonist) is a Small molecule (MW ~450, non-peptide). First non-peptide GLP-1R agonist approved (2025). Activates GLP-1R via allosteric (not orthosteric) binding — enabling oral bioavailability without peptide backbone. Biased agonism profile differs from peptide GLP-1R agonists. ATTAIN Phase 3: ~14.7% weight reduction at 36 weeks.
Research Applications
Allosteric GLP-1R Agonism
Allosteric vs orthosteric receptor binding comparison research
Oral Bioavailability
No injection stress confound — oral GLP-1R biology in rodent models
Biased Signalling
Small molecule vs peptide GLP-1R agonist downstream bias
Obesity Research
ATTAIN Phase 3 reference — 14.7% weight reduction at 36 weeks
vs Injectable GLP-1R
Mechanism and downstream signalling comparison
Quick Specs
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | 2211316-73-5 |
| Identity | MS molecular weight confirmed — every batch |
| Peptide Type | Small Molecule GLP-1 Receptor Agonist |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | -20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Shelf Life | 24 months sealed |
Certificate of Analysis (COA)
Frequently Asked Questions
Frequently asked questions
A seemingly elegant design can quickly begin to bloat with unexpected content or break under the weight of actual activity. Fake data can ensure a nice looking layout but it doesn’t reflect what a living, breathing application must endure. Real data does.
Websites in professional use templating systems. Commercial publishing platforms and content management systems ensure that you can show different text, different data using the same template. When it’s about controlling hundreds of articles, product pages for web shops.
A seemingly elegant design can quickly begin to bloat with unexpected content or break under the weight of actual activity. Fake data can ensure a nice looking layout but it doesn’t reflect what a living, breathing application must endure. Real data does.
Websites in professional use templating systems. Commercial publishing platforms and content management systems ensure that you can show different text, different data using the same template. When it’s about controlling hundreds of articles, product pages for web shops.
Reviews
Clear filtersThere are no reviews yet.